Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Safety, Efficacy and Feasibility of Haploidentical Stem Cell Transplantation (Haplo-SCT) Using Post-Transplant Cyclophosphamide (PTCy) as an Alternative Donor Source for Patients Who Lack a Matched Sibling/Unrelated Donor Options
Sponsor: Loyola University
Terminated
Poor accrual
Other terminated trials from Loyola University
Other Acute Lymphocytic Leukemia trials with similar outcome
Listed as NCT03088709, this PHASE2 trial focuses on Acute Lymphocytic Leukemia and Acute Myeloid Leukemia and remains terminated or withdrawn. Sponsored by Loyola University, it has been updated 10 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
May 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
May 2021 — May 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Mar 2019 — Oct 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Loyola University
For direct contact, visit the study record on ClinicalTrials.gov .